Transport characteristics of fexofenadine in the Caco-2 cell model

Pharmaceutical Research

Volumn 21, Issue 8, 2004, Pages 1398-1404

  Petri, Niclas ^a   Tannergren, Christer ^a   Rungstad, David ^a   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

absorption; Caco 2; fexofenadine; GF 120918; P glycoprotein

Indexed keywords

ELACRIDAR; ERYTHROMYCIN; FEXOFENADINE; INDOMETACIN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; PROBENECID; RIFAMYCIN; VERAPAMIL;

ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PENETRATION; DRUG POTENCY; DRUG TRANSPORT; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IC 50; OXYGEN SATURATION; POLARIZATION; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIFFUSION; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEINS; PERMEABILITY; TERFENADINE;

EID: 4344594700     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000036913.90332.b1     Document Type: Article

References (36)

1. H. van de Waterbeemdand and E. Gifford. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2:192-204 (2003).
2. R. A. Prentis, Y. Lis, and S. R. Walker. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol 25:387-396 (1988).
3. M. A. Hamman, M. A. Bruce, B. D. Haehner-Daniels, and S. D. Hall. The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 69:114-121 (2001).
4. R. B. Kim, B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I. Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J. D. Schuetz, E. G. Schuetz, and G. R. Wilkinson. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-199 (2001).
5. Z. Wang, M. A. Hamman, S. M. Huang, L. J. Lesko, and S. D. Hall. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther. 71:414-420 (2002).
6. C. Lippert, J. Ling, P. Brown, S. Burmaster, M. Eller, L. Cheng, R. Thompson, and S. Weir. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm. Res. s390 (1999).
7. B. Davit, K. Reynolds, R. Yuan, F. Ajayi, D. Conner, E. Fadiran, B. Gillespie, C. Sahajwalla, S. M. Huang, and L. J. Lesko. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J. Clin. Pharmacol. 39:899-910 (1999).
8. S. Gupta, C. Banfield, B. Kantesaria, M. Marino, R. Clement, M. Affrime, and V. Batra. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. 23:451-466 (2001).
9. H. Lennernas, O. Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, and L. K. Paalzow. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9:1243-1251 (1992).
10. C. Tannergren, T. Knutson, L. Knutson, and H. Lennernas. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55:182-190 (2003).
11. C. Tannergren, N. Petri, L. Knutson, M. Hedeland, U. Bondesson, and H. Lennernas. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 74:423-436 (2003).
12. M. Cvetkovic, B. Leake, M. F. Fromm, G. R. Wilkinson, and R. B. Kim. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866-871 (1999).
13. M. D. Perloff, L. L. von Moltke, and D. J. Greenblatt. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J. Clin. Pharmacol. 42:1269-1274 (2002).
14. M. Maliepaard, G. L. Scheffer, I. F. Faneyte, M. A. van Gastelen, A. C. Pijnenborg, A. H. Schinkel, M. J. van De Vijver, R. J. Scheper, and J. H. Schellens. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458-3464 (2001).
15. D. Keppler, T. Kamisako, I. Leier, Y. Cui, A. T. Nies, and H. Tsujii. and J. Konig. Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. Adv. Enzyme Regul. 40:339-349 (2000).
16. J. E. Coutant, P. A. Westmark, P. A. Nardella, S. M. Walter, and R. A. Okerholm. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 570:139-148 (1991).
17. P. Anderle, E. Niederer, W. Rubas, C. Hilgendorf, H. Spahn-Langguth, H. Wunderli-Allenspach, H. P. Merkle, and P. Langguth. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 87:757-762 (1998).
18. J. Gao, O. Murase, R. L. Schowen, J. Aube, and R. T. Borchardt. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res. 18:171-176 (2001).
19. H. Lennernas, K. Palm, U. Fagerholm, and P. Artursson. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 127:103-107 (1996).
20. R. Evers, M. Kool, A. J. Smith, L. van Deemter, M. de Haas, and P. Borst. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer 83:366-374 (2000).
21. F. Tangand and R. T. Borchardt. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm. Res. 19:787-793 (2002).
22. R. Evers, G. J. Zaman, L. van Deemter, H. Jansen, J. Calafat, L. C. Oomen, R. P. Oude Elferink, P. Borst, and A. H. Schinkel. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97:1211-1218 (1996).
23. M. P. Draper, R. L. Martell, and S. B. Levy. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer 75:810-815 (1997).
24. R. Masereeuw, A. P. van Pelt, S. H. van Os, P. H. Willems, P. Smits, and F. G. Russel. Probenecid interferes with renal oxidative metabolism: a potential pitfall in its use as an inhibitor of drug transport. Br. J. Pharmacol. 131:57-62 (2000).
25. I. Tamai, J. Nezu, H. Uchino, Y. Sai, A. Oku, M. Shimane, and A. Tsuji. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:251-260 (2000).
26. D. Kobayashi, T. Nozawa, K. Imai, J. Nezu, A. Tsuji, and I. Tamai. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306:703-708 (2003).
27. S. R. Vavricka, J. Van Montfoort, H. R. Ha, P. J. Meier, and K. Fattinger. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172 (2002).
28. O. Fardel, V. Lecureur, P. Loyer, and A. Guillouzo. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem. Pharmacol. 49:1255-1260 (1995).
29. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glyco protein. Pharm. Res. 16:408-414 (1999).
30. T. Russell, M. Stoltz, and S. Weir. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin. Pharmacol. Ther. 64:612-621 (1998).
31. M. B. Lande, N. A. Priver, and M. L. Zeidel. Determinants of apical membrane permeabilities of barrier epithelia. Am. J. Physiol. 267:C367-C374 (1994).
32. U. Fagerholm, D. Nilsson, L. Knutson, and H. Lennernas. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drug. Acta Physiol. Scand. 165:315-324 (1999).
33. R. Sandstrom, A. Karlsson, L. Knutson, and H. Lennernas. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15:856-862 (1998).
34. M. D. Troutmanand and D. R. Thakker. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 20:1210-1224 (2003).
35. J. Kelder, P. D. Grootenhuis, D. M. Bayada, L. P. Delbressine, and J. P. Ploemen. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16:1514-1519 (1999).
36. S. Winiwarter, N. M. Bonham, F. Ax, A. Hallberg, H. Lennernas, and A. Karlen. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41:4939-4949 (1998).